Meyka Pro banner
Sight Sciences, Inc.

Sight Sciences, Inc. Fundamental Analysis (NASDAQ: SGHT)

SGHTNASDAQ
HealthcareMedical - Devices
$8.32
$0.04(0.48%)
U.S. Market opens in 3h 4m

Sight Sciences, Inc. Fundamental Analysis (NASDAQ: SGHT)

Sight Sciences, Inc. (NASDAQ: SGHT) shows weak financial fundamentals with a PE ratio of -15.11, profit margin of -35.69%, and ROE of -50.64%. The company generates $0.1B in annual revenue with weak year-over-year growth of -3.13%.

Key Strengths

Cash Position17.59%
PEG Ratio-0.26
Current Ratio4.95

Areas of Concern

ROE-50.64%
Operating Margin-33.43%
We analyze SGHT's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -59.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-59.1/100

We analyze SGHT's fundamental strength across five key dimensions:

Efficiency Score

Weak

SGHT struggles to generate sufficient returns from assets.

ROA > 10%
-28.37%

Valuation Score

Excellent

SGHT trades at attractive valuation levels.

PE < 25
-15.11
PEG Ratio < 2
-0.26

Growth Score

Moderate

SGHT shows steady but slowing expansion.

Revenue Growth > 5%
-3.13%
EPS Growth > 10%
28.16%

Financial Health Score

Excellent

SGHT maintains a strong and stable balance sheet.

Debt/Equity < 1
0.79
Current Ratio > 1
4.95

Profitability Score

Weak

SGHT struggles to sustain strong margins.

ROE > 15%
-5064.40%
Net Margin ≥ 15%
-35.69%
Positive Free Cash Flow
No

Key Financial Metrics

Is SGHT Expensive or Cheap?

P/E Ratio

SGHT trades at -15.11 times earnings. This suggests potential undervaluation.

-15.11

PEG Ratio

When adjusting for growth, SGHT's PEG of -0.26 indicates potential undervaluation.

-0.26

Price to Book

The market values Sight Sciences, Inc. at 8.70 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

8.70

EV/EBITDA

Enterprise value stands at -19.30 times EBITDA. This is generally considered low.

-19.30

How Well Does SGHT Make Money?

Net Profit Margin

For every $100 in sales, Sight Sciences, Inc. keeps $-35.69 as profit after all expenses.

-35.69%

Operating Margin

Core operations generate -33.43 in profit for every $100 in revenue, before interest and taxes.

-33.43%

ROE

Management delivers $-50.64 in profit for every $100 of shareholder equity.

-50.64%

ROA

Sight Sciences, Inc. generates $-28.37 in profit for every $100 in assets, demonstrating efficient asset deployment.

-28.37%

Following the Money - Real Cash Generation

Operating Cash Flow

Sight Sciences, Inc. generates limited operating cash flow of $-23.20M, signaling weaker underlying cash strength.

$-23.20M

Free Cash Flow

Sight Sciences, Inc. generates weak or negative free cash flow of $-23.29M, restricting financial flexibility.

$-23.29M

FCF Per Share

Each share generates $-0.43 in free cash annually.

$-0.43

FCF Yield

SGHT converts -5.13% of its market value into free cash.

-5.13%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-15.11

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.26

vs 25 benchmark

P/B Ratio

Price to book value ratio

8.70

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.51

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.79

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.95

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.51

vs 25 benchmark

ROA

Return on assets percentage

-0.28

vs 25 benchmark

ROCE

Return on capital employed

-0.33

vs 25 benchmark

How SGHT Stacks Against Its Sector Peers

MetricSGHT ValueSector AveragePerformance
P/E Ratio-15.1131.50 Better (Cheaper)
ROE-50.64%422.00% Weak
Net Margin-35.69%19867.00% Weak
Debt/Equity0.790.53 Weak (High Leverage)
Current Ratio4.955.56 Strong Liquidity
ROA-28.37%1571.00% Weak

SGHT outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Sight Sciences, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

151.01%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

0.67%

Industry Style: Defensive, Growth, Innovation

Growing

FCF CAGR

17.23%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ